Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
144 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02626065 | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies(PAIR) | completed | Phase 4 | 32 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01431430 | VITamine D Supplementation in RenAL Transplant Recipients - VITALE(VITALE) | completed | Phase 4 | 538 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 8, 2025 |
| clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT05486182 | Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer(ESTROTIMP) | active not recruiting | Phase 4 | 153 | GE HealthcareINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04874207 | Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib(RePERSO) | completed | Phase 4 | 110 | Rennes University HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04861181 | NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.(NIRAPK) | terminated | Phase 4 | 12 | Hospices Civils de LyonOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT03849131 | Patient-Reported AutoImmunity Secondary to Cancer immunothErapy(PRAISE) | active not recruiting | Phase 4 | 905 | University Hospital, Strasbourg, FranceOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT01926496 | Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% | completed | Phase 4 | 485 | LEO PharmaINDUSTRY | 3 | Mar 7, 2025 | clinicaltrials |
| NCT05387525 | A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp(AKtive) | active not recruiting | Phase 4 | 447 | Almirall, S.A.INDUSTRY | 6 | Feb 11, 2025 | clinicaltrials |
| NCT06807034 | Impact of the Oral Microbiota on Relapse in HNSCC Patients(MICR-ORL) | active not recruiting | Phase 4 | 100 | Institut Sainte CatherineOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04289805 | Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)(fAMHOPE) | terminated | Phase 4 | 96 | Erasme University HospitalOTHER | 3 | Jan 31, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT03752216 | NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.(NiQoLe) | completed | Phase 4 | 141 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT04825574 | Study for Patients Previously Treated in Avapritinib Clinical Trials | completed | Phase 4 | 2 | Blueprint Medicines CorporationINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT06582186 | Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm(VORIPRECI) | not yet recruiting | Phase 4 | 30 | University Hospital, GrenobleOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04989491 | Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft(REPLY) | recruiting | Phase 4 | 120 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT03301857 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | completed | Phase 4 | 85 | AmgenINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 | clinicaltrials |
| NCT02768532 | Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease(VEDO-PREDIRESP) | terminated | Phase 4 | 47 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT02484677 | Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy(5-FU) | completed | Phase 4 | 12 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT01946672 | Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer(SENTIJAMBE) | completed | Phase 4 | 44 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI) | terminated | Phase 4 | 119 | University Hospital, AngersOTHER_GOV | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04875026 | Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial | completed | Phase 4 | 146 | Pierre Fabre MedicamentINDUSTRY | 4 | Sep 19, 2022 | clinicaltrials |
| NCT03333655 | Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy | completed | Phase 4 | 15 | Hoffmann-La RocheINDUSTRY | 5 | Aug 12, 2022 | clinicaltrials |
| NCT01100879 | Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy(AOC-MM) | terminated | Phase 4 | 3 | Vifor PharmaINDUSTRY | 2 | May 9, 2022 | clinicaltrials |
| NCT03449758 | Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis(SariPRO) | completed | Phase 4 | 84 | SanofiINDUSTRY | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04459221 | Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students(PROM SSCOL) | completed | Phase 4 | 355 | Centre Hospitalier Universitaire de la RéunionOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT00761371 | Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients | completed | Phase 4 | 52 | MEDA Pharma GmbH & Co. KGINDUSTRY | 2 | Feb 7, 2022 | clinicaltrials |
| NCT00777127 | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses(LEIDA) | completed | Phase 4 | 258 | MEDA Pharma GmbH & Co. KGINDUSTRY | 3 | Feb 7, 2022 | clinicaltrials |
| NCT03607149 | Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies(PKAPIR) | completed | Phase 4 | 11 | Centre Georges Francois LeclercOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03849365 | Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer | terminated | Phase 4 | 23 | Steba Biotech S.A.OTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT00381095 | A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer(COPE) | terminated | Phase 4 | 152 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 19 | Jan 20, 2021 | clinicaltrials |
| NCT01739764 | An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | completed | Phase 4 | 215 | Hoffmann-La RocheINDUSTRY | 25 | Jan 7, 2021 | clinicaltrials |
| NCT01588184 | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | completed | Phase 4 | 95 | Hoffmann-La RocheINDUSTRY | 21 | Nov 5, 2020 | clinicaltrials |
| NCT04298684 | Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes(METNODTHYR) | unknown | Phase 4 | 90 | Centre Hospitalier Universitaire de la GuadeloupeOTHER | 3 | Sep 11, 2020 | clinicaltrials |
| NCT00858754 | Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects | withdrawn | Phase 4 | 0 | Bausch Health Americas, Inc.INDUSTRY | 4 | Nov 29, 2019 | clinicaltrials |
| NCT01525550 | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 4 | 106 | PfizerINDUSTRY | 15 | Jul 30, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials